and he's 99% right
That's because CAR-Ts is a new therapy and analysts have no clue, analyst keep upping KITE target.KITE multibagger for 2015
make money- bought
GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
ZIOPHARM Oncology Upgraded to “Outperform” $15 Target at BMO Capital Markets
ZIOPHARM Oncology Upgraded to “Outperform” at BMO Capital Markets
January 14th, 2015 - 0 comments - Filed Under - by John Miller
ZIOPHARM Oncology logoZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by stock analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a report issued on Wednesday.The firm raises to $15.00 price target on the stock,
bluebird bio (BLUE) To Present At The 33rd Annual J.P. Morgan Healthcare Conference
bluebird bio, Inc. (Nasdaq: BLUE) today announced that management will present at the 33rd annual J.P.BioMorgan Healthcare Conference on Wednesday, January 14, 2015 at 2:30 p.m. PST. The conference is being held January 12-15, 2015 at the Westin St. Francis in San Francisco.
Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan Conatus Pharmaceuticals 56 minutes ago GlobeNewswire
The Fly On The Wall Breaking News
09:00 AM EST
bluebird bio added to Focus List at Roth Capital »Roth Capital expects bluebird bio (BLUE) to look to develop CART-T cancer treatments this year, in partnership with Celgene (CELG).
all in on this baby.